Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence

FDA discusses an overview of the assessment of risk factors with respect to the control of impurities and recommendations for documenting the risk-based determination.
Presenter:
Brian Connell, Division of Lifecycle API

Learn more at: https://www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - https://www.fda.gov/cdersbia   
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2021 Playlist -    • 2021 CDER Small Business and Industry...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance    
SBIA Training Resources - https://www.fda.gov/cderbsbialearn  
Twitter -   / fda_drug_info    
Email - [email protected]  
Phone - (301) 796-6707 I (866) 405-5367